Opinion
Video
Mohamad Baker Berjaoui, MD, on WATER and WATER II findings in BPH
Author(s):
Key Takeaways
- Aquablation therapy significantly reduced IPSS scores by approximately 15 points, regardless of prostate size, over five years.
- Qmax showed substantial improvement, increasing from around 8.5 to 17 in both WATER and WATER II trials.
"This study basically [looks at] WATER and WATER II over 5 years' follow-up," says Mohamad Baker Berjaoui, MD.
In this video, Mohamad Baker Berjaoui, MD, provides an overview of the BJUI Compass paper, “WATER versus WATER II 5-year update: Comparing Aquablation therapy for benign prostatic hyperplasia in 30–80-cm3 and 80–150-cm3 prostates.” Berjaoui is a urology resident at the University of Toronto in Ontario, Canada.
Transcription:
Please provide an overview of this study and its notable findings.
This study basically [looks at] WATER and WATER II over 5 years' follow-up. WATER is a randomized clinical trial that compared Aquablation treatment for prostates that are 30 to 80 ccs to TURP. WATER II evaluated Aquablation in prostates measuring 80 to 150 ccs. We presented the data for 5 years' follow-up for combined WATER and WATER II, and it showed significant decrease in the IPSS, basically around a 15-point drop regardless of the prostate size. It also showed significant improvement in Qmax. Basically, I think on average, it was somewhere around 8.5 or 8.6 for both studies, and then it went up to 17. That's also a significant improvement. It showed that the complication rates are really minimal, and preservation of sexual function was excellent. In terms of retreatment rate, which is the most important over the long term and the 5 years' follow-up, it was shown to be less than 4% overall, regardless of the prostate size.
This transcript was AI generated and edited by human editors for clarity.
